Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.6% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

7(77.8%)

N/A

1(11.1%)

Phase 3

1(11.1%)

9Total

Phase 2(7)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05316493Phase 2Recruiting

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

Role: lead

NCT05316467Phase 2Terminated

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

Role: lead

NCT04276532Not ApplicableActive Not Recruiting

Sentinel Lymph Node Sampling for Patients With Middle-high Risk Endometrial Cancer Confined to the Uterus

Role: lead

NCT06390904Phase 2Active Not Recruiting

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients

Role: lead

NCT06379113Phase 2Recruiting

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Role: lead

NCT05316935Phase 2Recruiting

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Role: lead

NCT04683237Phase 2Withdrawn

Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

Role: lead

NCT03675139Phase 3Completed

MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

Role: lead

NCT01968317Phase 2Completed

Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma

Role: lead

All 9 trials loaded